Insiders · SMMT

Yu Xia

Director at Summit Therapeutics Inc. (SMMT) since January 2023

Yu Xia has filed 6 insider reports with the SEC since January 2023, as director at Summit Therapeutics Inc. (SMMT). Yu Xia made no open-market purchases or sales in the last 12 months. The latest filing, on January 6, 2026, reports grant or award at Summit Therapeutics Inc. (SMMT).

Filings
6
Companies
1
Bought on market
$57.7M
Sold on market
None

Companies where Yu Xia is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Summit Therapeutics Inc. logo
SMMT
Summit Therapeutics Inc.
Directorsince January 2023$57.7M$1.80$9.95+453%Jan 6, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Compare Yu Xia with

Other insiders at the same companies

Questions about Yu Xia

What is Yu Xia's role at Summit Therapeutics Inc.?
Yu Xia reports to the SEC as director at Summit Therapeutics Inc. (SMMT), according to the latest filing on January 6, 2026.
Has Yu Xia bought or sold stock recently?
The most recent open-market purchase was on October 21, 2025: bought 533,617 shares of Summit Therapeutics Inc. (SMMT) for $10M at an average of $18.74.
How do I get alerts when Yu Xia files?
Follow Yu Xia on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Yu Xia (SEC CIK 0001963544). Totals count each trade once, skipping amendments whose original is on file, from Jan 26, 2023 on. View on SEC EDGAR · Get this as JSON